DSFIR:EURONEXT AMSTERDAMDSM-Firmenich AG Analysis

DSM‑Firmenich is trading at €59, just below its 20‑day SMA of €59.12 and well under the 50‑day (€63.84) and 200‑day (€75.61) averages, signaling a short‑term bearish bias. The RSI sits at 44, indicating neutral momentum, while the MACD histogram is positive and the signal line is deemed bullish, creating a mixed technical picture. Volume has been decreasing and 30‑day volatility is high at 44%, suggesting price swings could be sharp despite the stock’s low beta of 0.17. Fundamentals are weak: profit margin is –12%, free cash flow is negative, and debt‑to‑equity is an elevated 28.6, while the forward PE of 15.3 still lags the current PE of 48.8. The dividend yield looks attractive at 4.24% but the payout ratio exceeds 200%, raising concerns about sustainability. A recent €1.5 bn bond issuance improves liquidity, and the sale of the ANH business for €2.2 bn could sharpen focus on higher‑margin segments. Analysts maintain a “buy” rating with a median target of €81.5, implying upside, but the DCF fair value of €41.55 suggests the market may be overvaluing the stock.